Abstract
Small cell lung cancer (SCLC) is a recalcitrant cancer that has an extremely high rate of proliferation and recurrence. On average, every year there are more than 200,000 new diagnosed cases worldwide with only an estimated 15% survival rate. According to previous research, the protein SRY-box transcription factor 2 (SOX2) is known to be overexpressed in SCLC. To establish its candidacy as a possible SCLC vaccine target, SOX2 was evaluated for immunogenicity using in silico methods. The secondary structure of SOX2 was analyzed for complexity followed by the prediction of B cell and T cell epitopes. These epitopes were then evaluated for tolerability, efficacy, and cytotoxicity using different web-based servers. Our data predict that SOX2 is a good candidate target protein that can elicit a strong immune response against SCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
